Innovative nonviral gene delivery strategies for engineering human mesenchymal stem cell phenotypes toward clinical applications

Abstract excerpt

Although human mesenchymal stem cells (hMSCs) have been used in many clinical trials, variable outcomes have resulted in no FDA-approved hMSC treatment. However, research into developing hMSC therapies for many diseases continues. An approach to manipulate hMSCs for therapeutic applications is gene delivery. Nonviral gene delivery is safer and more flexible than viral vectors, but much less efficient, especially...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mesenchymal stem cell research
• Share to RNA Interference and Gene Delivery
• Share to Virus-based gene therapy research